<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882684</url>
  </required_header>
  <id_info>
    <org_study_id>CAALC-005-LiSen</org_study_id>
    <nct_id>NCT03882684</nct_id>
  </id_info>
  <brief_title>Role of Genomic Imprinting in Cancer Diagnosis</brief_title>
  <official_title>Role of Genomic Imprinting in Cancer Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Alliance Against Lung Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LiSen Imprinting Diagnostic Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Alliance Against Lung Cancer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current research focus for cancer diagonosis is classical genetics, named &quot;driving
      genes&quot;. However, not all cancer patients have typical genetic alterations, especially at
      early stage. In the past dacades, accumulating evidences have revealed that more than 80%
      diseases are closely related to epigenetic changes. The normally silenced copy of imprinted
      genes are reactivated at early stage of cancers, and finally proceed to copy number
      variation. This study will screen for a panel of imprinted genes and build quantitative
      models to assist the diagnosis of multiple cancers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of imprinting cancer early detection</measure>
    <time_frame>In the middle of the study, an average of 15 months</time_frame>
    <description>Number of patients &quot;declared positive&quot; with the imprinting early detection among the patients suffered from cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of imprinting cancer early detection</measure>
    <time_frame>In the middle of the study, an average of 15 months</time_frame>
    <description>Number of patients &quot;declared negative&quot; with the imprinting early detection among the patients who are with benign tumors or other diseases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the sensitivity of the imprinting detection versus cytopathology</measure>
    <time_frame>In the middle of the study, an average of 15 months</time_frame>
    <description>Number of patients &quot;declared positive&quot; with the imprinting early detection versus patients &quot;declared positive&quot; with the cytopathology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the specificity of the imprinting detection versus cytopathology</measure>
    <time_frame>In the middle of the study, an average of 15 months</time_frame>
    <description>Number of patients &quot;declared negative&quot; with the imprinting early detection versus patients &quot;declared negative&quot; with the cytopathology</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Early Diagnosis</condition>
  <condition>Cancer</condition>
  <condition>Biomarker</condition>
  <condition>Genomic Imprinting</condition>
  <arm_group>
    <arm_group_label>Cancer patients</arm_group_label>
    <description>The patients receive the surgery according to the indication of surgery. The diagnosis is confirmed by pathology of removed tissue. The result of imprinting detection are used as cancer group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign tumor and other disease patients</arm_group_label>
    <description>Patients ruled out the possibility of malignancy according to biopsy pathology are used as negative control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>In-situ imprinting detection</intervention_name>
    <description>The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.</description>
    <arm_group_label>Benign tumor and other disease patients</arm_group_label>
    <arm_group_label>Cancer patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      This study collects biopsies samples including but not limited to bronchoscopy biopsy,
      bronchial lavage fluid, fine needle aspiration, cystoscopy biopsy, urine samples, colonoscopy
      biopsy.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with suspicious cancer in Zhongshan Hospital from July 2017 till the end
        of this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with suspicious cancer by ultrasound, CT or endoscope.

          -  Biopsy samples available.

          -  Male or female patients aged â‰¥ 18 years.

          -  Participants signed informed consent form.

        Exclusion Criteria:

          -  Age under 18 years.

          -  Severe cardiovascular diseases.

          -  Central nervous system diseases.

          -  Mental disorder.

          -  Pregnant.

          -  Individuals unwilling to sign the IRB-approved consent form and unwilling to follow
             the protocol to submit the serial urine for test after surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunxue Bai, MD</last_name>
    <phone>18621170011</phone>
    <email>bai.chunxue@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunxue Bai, MD</last_name>
      <phone>18621170011</phone>
      <email>bai.chunxue@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Dawei Yang, MD</last_name>
      <phone>13564703813</phone>
      <email>yang_dw@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Feinberg AP. The Key Role of Epigenetics in Human Disease Prevention and Mitigation. N Engl J Med. 2018 Apr 5;378(14):1323-1334. doi: 10.1056/NEJMra1402513. Review.</citation>
    <PMID>29617578</PMID>
  </reference>
  <reference>
    <citation>Jelinic P, Shaw P. Loss of imprinting and cancer. J Pathol. 2007 Feb;211(3):261-8. Review.</citation>
    <PMID>17177177</PMID>
  </reference>
  <reference>
    <citation>Haig D. Maternal-fetal conflict, genomic imprinting and mammalian vulnerabilities to cancer. Philos Trans R Soc Lond B Biol Sci. 2015 Jul 19;370(1673). pii: 20140178. doi: 10.1098/rstb.2014.0178. Review.</citation>
    <PMID>26056362</PMID>
  </reference>
  <reference>
    <citation>Nilendu P, Sharma NK. Epigenomic Hard Drive Imprinting: A Hidden Code Beyond the Biological Death of Cancer Patients. J Cancer Prev. 2017 Dec;22(4):211-218. doi: 10.15430/JCP.2017.22.4.211. Epub 2017 Dec 30. Review.</citation>
    <PMID>29302578</PMID>
  </reference>
  <reference>
    <citation>Uribe-Lewis S, Woodfine K, Stojic L, Murrell A. Molecular mechanisms of genomic imprinting and clinical implications for cancer. Expert Rev Mol Med. 2011 Jan 25;13:e2. doi: 10.1017/S1462399410001717. Review.</citation>
    <PMID>21262060</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Alliance Against Lung Cancer</investigator_affiliation>
    <investigator_full_name>Bai Chunxue</investigator_full_name>
    <investigator_title>Chair</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

